Form 4: Wave Life Sciences Director Sells Shares

Wave Life Sciences Director Adrian Rawcliffe sold 16,115 ordinary shares for a weighted-average price of $6.79 per share, pursuant to a pre-arranged trading plan.

Summary

• Adrian Rawcliffe, a Director of Wave Life Sciences Ltd. (WVE), reported a sale of ordinary shares.
• The transaction involved the disposition of 16,115 ordinary shares.
• The shares were sold at a weighted-average price of $6.79 per share, with individual sale prices ranging from $6.64 to $7.00.
• The sale was executed on November 13, 2025.
• This transaction was conducted under a Rule 10b5-1 trading plan, which was adopted by Adrian Rawcliffe on August 5, 2025.
• Following this transaction, Adrian Rawcliffe beneficially owns 12,700 ordinary shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction (Rule 10b5-1 plan) and does not reflect new information about the company's performance or prospects.

Positives

• The sale was conducted pursuant to a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to immediate, non-public information, which enhances transparency.

Negatives

• A director reducing their direct ownership in the company, even if pre-planned, can sometimes be perceived as a slight reduction in alignment of interests with shareholders.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A director's reduction in direct ownership, even if pre-planned, slightly reduces the alignment of interests, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Keywords

Wave Life Sciences, WVE, Adrian Rawcliffe, Form 4, Insider Transaction, Share Sale, Director, 10b5-1 Plan